TELO (Telomir Pharmaceuticals) Marketable Securities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TELO Telomir Pharmaceuticals Inc TELO
14 GF Score
Price $1.18
! 3 Warning Signs
View Full Analysis

What is Telomir Pharmaceuticals Marketable Securities?

Telomir Pharmaceuticals TELO +2.17% 14 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates TELO with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Telomir Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Telomir Pharmaceuticals  (NAS:TELO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Telomir Pharmaceuticals Marketable Securities Related Terms

Telomir Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Telomir Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals Marketable Securities Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00 0.00 0.00

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TELO
14GF Score
Telomir Pharmaceuticals Inc TELO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telomir Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Telomir Pharmaceuticals (TELO) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Telomir Pharmaceuticals and its competitors.
Is Telomir Pharmaceuticals' Marketable Securities too high?
Telomir Pharmaceuticals' current Marketable Securities is $0.00 Mil. Overall, Telomir Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Telomir Pharmaceuticals' Marketable Securities compare to INO and ELTX?
Telomir Pharmaceuticals' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Telomir Pharmaceuticals and its competitors. Telomir Pharmaceuticals's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telomir Pharmaceuticals stock overvalued right now?
Telomir Pharmaceuticals (TELO) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Telomir Pharmaceuticals' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Telomir Pharmaceuticals (TELO), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telomir Pharmaceuticals Business Description

Address 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
14GF Score

Get the complete analysis for TELO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price